Study of QLC1101 for advanced solid tumors with KRAS G12D mutation
Part of Cancer, Genetic & congenital clinical trials.
This trial tests a new drug, QLC1101, given with other treatments for people with advanced solid tumors that have a specific change in the KRAS gene called G12D. It aims to see if the combination is safe and helps shrink or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer is advanced, meaning it has spread or cannot be removed by surgery.
- Your tumor has a specific change in the KRAS gene called G12D.
- You have tried standard treatments and they no longer work, you cannot handle them, or you choose not to have them.
- You have at least one tumor that can be measured on a CT or MRI scan.
- You are well enough to do daily activities (ECOG score 0 or 1).
- Your cancer has not spread to the brain causing symptoms, or you have not had active brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, QLC1101, for people with advanced solid tumors that have a specific genetic change called KRAS G12D. It may be an option if you have tried other treatments or cannot take them.
This trial tests a new drug called KQB548 for people with certain advanced cancers (pancreatic, colorectal, or lung) that have a specific genetic change called KRAS G12D. It's for those whose cancer has continued to grow despite previous treatments.
This trial tests an experimental drug, QLS1209, for people with advanced solid tumors that have specific genetic changes (CCNE1 amplification, FBXW7 mutation, or PPP2R1A mutation). It aims to see if the drug is safe and effective for those who have not responded to standard treatments or have no standard options.
This trial tests a new drug called QLC5508, given in combination with other treatments, for people with advanced solid tumors that have stopped responding to standard therapy or who haven't had treatment yet. The goal is to see if the combination can shrink tumors or slow their growth.
This trial tests a combination of two experimental drugs (SY-5933 and CT-707) for people with advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to see if the combination is safe and effective.
This early-stage trial tests a new drug called LT-010391 designed to target a specific genetic mutation (KRAS G12D) found in some solid tumors. It's for patients whose cancer has progressed despite standard treatments or who cannot tolerate them.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.